<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026116</url>
  </required_header>
  <id_info>
    <org_study_id>SHBCC09007</org_study_id>
    <nct_id>NCT01026116</nct_id>
  </id_info>
  <brief_title>A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old</brief_title>
  <official_title>Comparing EC-wP Versus EP-wP as Adjuvant Therapy for Breast Cancer Patients Less Than 40 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Manifold data revealed that young breast cancer patients are characterized by aggressive&#xD;
      clinical history. The purpose of this study is to evaluate the efficacy and safety of&#xD;
      different strategies incorporating paclitaxel to anthracycline-based regimens in young breast&#xD;
      cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 23, 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>every one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>menstrual resumption rate</measure>
    <time_frame>12 months after chemotherapy</time_frame>
    <description>Resumption of menses was defined as at least 2 consecutive menstruations, or at least 1 menstruation with a confirmed premenopausal level of FSH and estradiol after chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>every one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">521</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>EC-wP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>epirubicin/cyclophosphamide followed weekly paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EP-wP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>epirubicin/paclitaxel followed by weekly paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>75 mg/m2 every-3-week for four cycles</description>
    <arm_group_label>EC-wP</arm_group_label>
    <arm_group_label>EP-wP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>600 mg/m2 every-3-week for four cycles</description>
    <arm_group_label>EC-wP</arm_group_label>
    <arm_group_label>EP-wP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks</description>
    <arm_group_label>EC-wP</arm_group_label>
    <arm_group_label>EP-wP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients, age 18~40&#xD;
&#xD;
          -  Unilateral, operable, histologically confirmed adenocarcinoma of the breast&#xD;
&#xD;
          -  Stage I-III&#xD;
&#xD;
          -  Primary surgery with clear margins plus axillary dissection&#xD;
&#xD;
          -  Able to start protocol Rx within 8 weeks of surgery&#xD;
&#xD;
          -  Histological or cytological confirmation of estrogen-receptor positive (ER+) breast&#xD;
             cancer: the immunohistochemical cut-off for ER positive status was&#xD;
&#xD;
             1% or more staining in nuclei&#xD;
&#xD;
          -  HER-2 negative (IHC 0,1+ or 2+ with a negative in situ hybridization test by&#xD;
             chemotherapy&#xD;
&#xD;
          -  pathologically confirmed regional node-positive disease, or node-negative disease with&#xD;
             high-risk factors (primary tumor diameter &gt;10 mm when histological grade III, or tumor&#xD;
             diameter &gt;20 mm when histological grade II)&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Adequate cardiac, renal, hepatic and hematologic function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Bilateral breast cancer (synchronous or metachronous)&#xD;
&#xD;
          -  Prior radiation therapy, hormonal therapy and chemotherapy for breast cancer&#xD;
&#xD;
          -  Previous cancer (except treated basal cell and squamous cell carcinoma of the skin or&#xD;
             cancer of the uterine cervix)&#xD;
&#xD;
          -  HER-2 positive (IHC 3+ OR FISH+) and or triple-negative breast cancer&#xD;
&#xD;
          -  Documented history of cardiac disease contradiction anthracyclines&#xD;
&#xD;
          -  Concurrent serious illness&#xD;
&#xD;
          -  Peripheral neuropathy of CTC grade&gt;1&#xD;
&#xD;
          -  History of hypersensitivity to drugs formulated in Cremophor EL polyoxyethylated&#xD;
             castor oil), the vehicle used for commercial paclitaxel formulations&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhimin Shao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital, Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Breast Surgery, Cancer Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <last_update_submitted>May 9, 2020</last_update_submitted>
  <last_update_submitted_qc>May 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>Director of Breast Surgery Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

